精密科學 EXAS 深 滬
等待開盤 07-25 09:30:00 美东时间
48.77
+0.360
+0.74%
華盛通- 最 高49.93
- 今 開48.50
- 成交量 245.97万股
- 最 低 48.26
- 昨 收 48.41
- 總市值 92.18亿
- 52周最高 72.83
- 市盈率 靜 --
- 換手率 1.30%
- 52周最低 39.97
- 委 比 90.49%
- 總股本 1.89亿
- 歷史最高 159.54
- 量 比 1.14
- 振 幅 3.45%
- 歷史最低 4.67
- 每 手 1
- 風險率 7.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Exact Sciences gets Medicare coverage for its colorectal cancer test
Exact Sciences (NASDAQ:EXAS) has announced that its oncodetect test for detecting residual disease in colorectal cancer is now covered by Medicare. This coverage is provided through the Centers for M...
07-09 21:14
Forecasting The Future: 9 Analyst Projections For Exact Sciences
Across the recent three months, 9 analysts have shared their insights on Exact ...
07-09 03:01
Evercore ISI Group Maintains Outperform on Exact Sciences, Raises Price Target to $68
Evercore ISI Group analyst Vijay Kumar maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and raises the price target from $66 to $68.
07-08 20:57
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care
Cancer screening firms Guardant Health (NASDAQ:GH), Exact Sciences (NASDAQ:EXAS), and Labcorp (NYSE:LH), as well as HIV drugmaker Gilead (NASDAQ:GILD), traded higher on Friday after the Supreme Court ...
06-28 00:10
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out
BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and Exact Sciences.
06-26 03:16
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Barclays Maintains Overweight on Exact Sciences, Lowers Price Target to $65
Barclays analyst Luke Sergott maintains Exact Sciences (NASDAQ:EXAS) with a Overweight and lowers the price target from $75 to $65.
06-24 23:20
科学历史人物研究的当代价值（图）
转自：天津日报 由河南大象出版社出版的《中外著名科学家传记（五卷本）》，收集了《自然辩证法通讯》杂志40多年中所发表的200多位科学家的学术评传，在...
06-09 05:04
Exact Sciences Announced New Data To Be Presented From The Beta-CORRECT Clinical Validation Study At The 2025 American Society Of Clinical Oncology Annual Meeting
Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect, for recurrence monitoring in stage II–IV colorectal cancer.Whole-genome Oncodetect
05-28 18:07
